New antibody drug aims to tame Sjögren's symptoms
Disease control
Not yet recruiting
This study tests a new drug called ESG206 in 40 adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. The drug targets a protein to reduce disease activity. Participants will receive either ESG206 or a placebo to see if the drug safely impr…
Phase: PHASE2 • Sponsor: Shanghai Escugen Biotechnology Co., Ltd • Aim: Disease control
Last updated May 17, 2026 13:08 UTC